ESR1 and breast cancer: We have previously shown that boron-based 4-hydroxytamoxifen prodrugs are active antiestrogenic agents in vitro, with potencies exceeding that of tamoxifen in MCF-7 and T47D breast cancer cells the express ERα [21].